Stockscreener 앱 받기
14.93
0.13%
-0.06
전일 마감가:
$14.99
열려 있는:
$15.05
하루 거래량:
89,575
시가총액:
$1.77B
수익:
$398.20M
순이익/손실:
$71.41M
주가수익비율:
14.78
EPS:
1.01
순현금흐름:
$61.86M
1주 성능:
-0.53%
1개월 성능:
-1.32%
6개월 성능:
+16.50%
1년 성능:
-13.02%
1일 변동 폭
$14.82
$15.09
52주 변동 폭
$11.09
$17.77
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
305-420-3200
주소
355 Alhambra Circle, Suite 1250, Coral Gables
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Zacks Investment Research
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Zacks Investment Research
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
Catalyst Pharmaceuticals Inc (CPRX) 매출 2024
CPRX은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 398.20M 달러로 보고했으며, 전년대비 +85.90% 상승했습니다.
Catalyst Pharmaceuticals Inc (CPRX) 순이익 2024
CPRX은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 71.41M 달러로 보고했으며, 전년대비 -14.05% 감소했습니다.
Catalyst Pharmaceuticals Inc (CPRX) 현금흐름 2024
2023-12-31 종료 분기에 CPRX은 현금흐름(지난 12개월)으로 61.86M 달러를 기록했으며, 전년 대비 -46.68% 감소했습니다.
Catalyst Pharmaceuticals Inc (CPRX) 주당 순이익 2024
CPRX이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 0.61달러이며, 전년 대비 -17.57% 감소했습니다.
Catalyst Pharmaceuticals Inc 주식 (CPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tierney David S | Director |
Apr 08 '24 |
Sale |
15.68 |
25,000 |
392,000 |
348,874 |
| Elsbernd Brian | Chief Compliance/Legal Officer |
Mar 27 '24 |
Sale |
16.44 |
25,000 |
411,000 |
124,433 |
| DENKHAUS DONALD A | Director |
Feb 05 '24 |
Option Exercise |
4.01 |
40,000 |
160,400 |
434,333 |
| MCENANY PATRICK J | Chairman of Board of Directors |
Jan 02 '24 |
Option Exercise |
1.13 |
250,000 |
282,500 |
4,385,256 |
| O'Keeffe Charles B | Director |
Jan 02 '24 |
Option Exercise |
1.13 |
60,000 |
67,800 |
681,724 |
| Tierney David S | Director |
Jan 02 '24 |
Option Exercise |
1.13 |
10,000 |
11,300 |
344,874 |
| Harper Molly | Director |
Dec 15 '23 |
Option Exercise |
5.78 |
10,000 |
57,800 |
10,000 |
| Harper Molly | Director |
Dec 15 '23 |
Sale |
14.39 |
14,000 |
201,420 |
0 |
| Tierney David S | Director |
Dec 12 '23 |
Option Exercise |
1.13 |
50,000 |
56,500 |
383,541 |
| Tierney David S | Director |
Dec 12 '23 |
Sale |
13.32 |
50,000 |
666,250 |
333,541 |
0.88%
0.79%
자본화:
|
볼륨(24시간):